Haemonetics (STU:HAZ) Ending Cash Position: €194 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:HAZ Haemonetics Corp STU:HAZ
80 GF Score
Price €89.50
GF Value €73.62
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Haemonetics Ending Cash Position?

Haemonetics STU:HAZ -0.56% 80 Ending Cash Position is €194 Mil as of Jun. 2026. GuruFocus rates STU:HAZ with a GF Score™ of 80/100 and a GF Value™ of €73.62 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Haemonetics's Ending Cash Position for the quarter that ended in Jun. 2026 was €194 Mil.

Haemonetics's quarterly Ending Cash Position declined from Dec. 2025 (€310 Mil) to Mar. 2026 (€212 Mil) and declined from Mar. 2026 (€212 Mil) to Jun. 2026 (€194 Mil).

Haemonetics's annual Ending Cash Position increased from Mar. 2024 (€164 Mil) to Mar. 2025 (€284 Mil) but then declined from Mar. 2025 (€284 Mil) to Mar. 2026 (€212 Mil).

Haemonetics Ending Cash Position Related Terms

Haemonetics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Haemonetics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Haemonetics Ending Cash Position Chart

Haemonetics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 235.62 265.69 164.50 283.76 212.31

Haemonetics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 253.94 252.56 310.32 212.31 193.90
STU:HAZ
80GF Score
Haemonetics Corp STU:HAZ
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Haemonetics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Haemonetics's Ending Cash Position for the fiscal year that ended in Mar. 2026 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=265.351+-53.045
=212

Haemonetics's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=213.042+-19.145
=194

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of €194 Mil mean?
Haemonetics (STU:HAZ) has a Ending Cash Position of €194 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Haemonetics and its competitors.
Is Haemonetics' Ending Cash Position too high?
Haemonetics' current Ending Cash Position is €194 Mil. Overall, Haemonetics has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Haemonetics' Ending Cash Position compare to LIVN and ITGR?
Haemonetics' Ending Cash Position of €194 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Medical Devices & Instruments company?
A good Ending Cash Position depends on the Medical Devices & Instruments industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Haemonetics and its competitors. Haemonetics's current Ending Cash Position is €194 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haemonetics stock overvalued right now?
Based on GuruFocus' analysis, Haemonetics (STU:HAZ) is currently considered Modestly Overvalued. The stock's GF Value™ is €73.62, compared to a current price of €89.50 — trading 21.6% above its estimated fair value. The current Ending Cash Position is €194 Mil. Haemonetics' overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Haemonetics (STU:HAZ), the current Ending Cash Position is €194 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Haemonetics (STU:HAZ) Overvalued in 2026?

Based on GuruFocus' analysis, Haemonetics stock appears to be overvalued. The current stock price of €89.50 is trading 21.6% above its estimated GF Value™ of €73.62. GuruFocus considers Haemonetics to be Modestly Overvalued.

Key valuation signals for STU:HAZ:

  • Ending Cash Position: €194 Mil
  • GF Value™: €73.62 vs. price of €89.50 (21.6% above fair value)
  • GF Score™: 80/100 with 4 warning signs

No single metric tells the full story. See the STU:HAZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Haemonetics Business Description

Other Exchanges HAE:USA
Address 125 Summer Street, Boston, MA, USA, 02110
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
80GF Score

Get the complete analysis for STU:HAZ

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€89.50
Price
€73.62
GF Value